Anti-LIN28 LIN28A Monoclonal Antibody

Overview

This product is an anti-LIN28A antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AFFE-12; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF, IP, Flow (as provided in the source record). Boster Bio Anti-LIN28 LIN28A Monoclonal Antibody catalog # M01966-1. Tested in WB, IHC, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human.

Key elements and design rationale

• Target: LIN28A (Protein lin-28 homolog A).
• Antibody format: Monoclonal; clone AFFE-12; isotype Rabbit IgG.
• Host: Rabbit.
• Species reactivity: Human (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

LIN28A (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): 'Translational enhancer' that drives specific mRNAs to polysomes and increases the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, inly, in mRNA stabilization. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression (By similarity). Suppressor of microRNA (miRNA) biogenesis, including that of let- 7, miR107, miR-143 and miR-200c. Specifically binds miRNA precursors (pre-miRNAs), recognizing an 5'-GGAG-3' motif found in pre-miRNA terminal loop, and recruits ZCCHC11/TUT4 uridylyltransferase. This results in the terminal uridylation of target pre-miRNAs (PubMed:19703396) (PubMed:22118463) (PubMed:22898984). Uridylated pre-miRNAs fail to be processed by Dicer and undergo degradation. The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state by preventing let-7-mediated differentiation of embryonic stem cells (By similarity). . Reported cellular localization context: Cytoplasm . Nucleus, nucleolus. Predominantly cytoplasmic (PubMed:22118463). Nucleolar localization observed in 10-15% of the nuclei in differentiated myotubes (By similarity). Shuttles between the cytoplasm and the nucleus. Localizes to cytoplasmic processing bodies and stress granules. . Tissue expression notes (as provided): Expressed in embryonic stem cells, placenta and testis. Tends to be up-regulated in HER2-overexpressing breast tumors. .

Research relevance and current trends

• Research context keywords from the source record include: DNA/RNA,Epigenetics and Nuclear Signaling,Translation.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
• Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
• Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
• Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.

Workflow ideas (metafield): Validate LIN28A antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect LIN28A expression by Western blot in cell or tissue lysates, Detect LIN28A in FFPE tissue sections by immunohistochemistry, Localize LIN28A by immunofluorescence/immunocytochemistry in cultured cells, Quantify LIN28A-positive cells by flow cytometry in single-cell suspensions, Enrich LIN28A by immunoprecipitation from lysates for downstream analysis

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 33 kDa; calculated MW: 22743 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 33 kDa
• Cellular localization (provided): Cytoplasm . Nucleus, nucleolus. Predominantly cytoplasmic (PubMed:22118463). Nucleolar localization observed in 10-15% of the nuclei in differentiated myotubes (By similarity). Shuttles between the cytoplasm and the nucleus. Localizes to cytoplasmic processing bodies and stress granules. .
• Tissue details (provided): Expressed in embryonic stem cells, placenta and testis. Tends to be up-regulated in HER2-overexpressing breast tumors. .

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.